Literature DB >> 9565989

Impaired cerebral glucose metabolism in myotonic dystrophy: a triplet-size dependent phenomenon.

D Annane1, M Fiorelli, B Mazoyer, S Pappata, B Eymard, H Radvanyi, C Junien, M Fardeau, P Merlet, P Gajdos, A Syrota, Y Sansom, D Duboc.   

Abstract

Myotonic dystrophy (DM) is caused by an expansion of a CTG triplet repeat sequence in the 3'-noncoding region of a protein kinase gene, yet the mechanism by which the triplet repeat expansion causes disease remains unknown. Impaired glucose penetration into brain tissues has been described in DM patients and is a phenomenon that remains unexplained. The present study shows that altered brain glucose metabolism is triplet repeat dependent. We studied brain glucose metabolism (CMRGlu, mumol/100 g/min) by the use of positron emission tomography and 18F-fluoro-2-deoxy-D-glucose in 11 ambulatory non-obese DM patients and in 11 age and sex matched healthy subjects. All subjects underwent a glucose tolerance test with plasma insulin determinations. The expansion of CTG triplet repeats was analyzed in patients with the probe cDNA25 after EcoRI digestion. As compared to controls, in DM patients, the CMRGlu was significantly decreased (26.26 +/- 5.05 vs. 33.43 +/- 2.18, mumol/100 g/min, P = 0.004), and after oral glucose loading, plasma insulin levels were significantly higher and plasma glucose levels remained unchanged (respectively, F = 11.21, P = 0.004 and F = 0.20, P = 0.66). Subsequently, the glucose/insulin ratio was significantly lower in DM patients (F = 6.25, P = 0.02). The length of the expansion of the CTG repeats correlated negatively with the CMRGlu (r2 = 0.63, P = 0.003) and positively with the area under the curve for insulin changes over time after oral glucose (r2 = 0.49, P = 0.016). We conclude that, in DM patients, the brain metabolism of glucose is impaired in a repeat dependent manner.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565989     DOI: 10.1016/s0960-8966(97)00144-2

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

1.  Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients.

Authors:  Vincenzo Romeo; E Pegoraro; F Squarzanti; G Sorarù; C Ferrati; M Ermani; P Zucchetta; F Chierichetti; C Angelini
Journal:  Neurol Sci       Date:  2010-09-15       Impact factor: 3.307

2.  Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2.

Authors:  Vincenzo Romeo; E Pegoraro; C Ferrati; F Squarzanti; G Sorarù; A Palmieri; P Zucchetta; L Antunovic; E Bonifazi; G Novelli; C P Trevisan; M Ermani; R Manara; C Angelini
Journal:  J Neurol       Date:  2010-03-11       Impact factor: 4.849

3.  Neuropathology does not Correlate with Regional Differences in the Extent of Expansion of CTG Repeats in the Brain with Myotonic Dystrophy Type 1.

Authors:  Kyoko Itoh; Maki Mitani; Kunihiko Kawamoto; Naonobu Futamura; Itaru Funakawa; Kenji Jinnai; Shinji Fushiki
Journal:  Acta Histochem Cytochem       Date:  2010-12-18       Impact factor: 1.938

4.  In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8.

Authors:  Dimitri Renard; Laurent Collombier; Christel Castelli; Jean-Pierre Pouget; Pierre-Olivier Kotzki; Vincent Boudousq
Journal:  BMC Neurol       Date:  2016-07-13       Impact factor: 2.474

Review 5.  Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS.

Authors:  Genevieve Gourdon; Giovanni Meola
Journal:  Front Cell Neurosci       Date:  2017-04-20       Impact factor: 5.505

Review 6.  Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1.

Authors:  Sylvia Nieuwenhuis; Kees Okkersen; Joanna Widomska; Paul Blom; Peter A C 't Hoen; Baziel van Engelen; Jeffrey C Glennon
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

Review 7.  Current Progress in CNS Imaging of Myotonic Dystrophy.

Authors:  Martina Minnerop; Carla Gliem; Cornelia Kornblum
Journal:  Front Neurol       Date:  2018-08-21       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.